CLINICAL TRIALS PROFILE FOR ARESTIN
✉ Email this page to a colleague
All Clinical Trials for ARESTIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00371332 ↗ | Effect of Adjunctive Treatment With Arestin on the Subgingival Microflora in Patients With Moderate to Advanced Periodontitis | Completed | OraPharma | Phase 3 | 2004-01-01 | The purpose of this study is to measure the antimicrobial effects of Arestin in subjects with moderate to advanced periodontal disease |
| NCT01517334 ↗ | Arestin - Use in Subjects With Peri-Implantitis (With Subgingival Microbiological Evaluation) | Completed | OraPharma | Phase 3 | 2012-05-01 | The objective of the study is to evaluate the safety, effectiveness and anti-microbial effects of Arestin (minocycline HCl) 1 mg Microspheres in the treatment of subjects with peri-implantitis, when used in combination with mechanical debridement. The hypothesis of the study is that Arestin in combination with mechanical debridement is more effective in the treatment of peri-implantitis when compared to mechanical debridement alone. The primary efficacy measure will be the reduction of probing depth at Day 180 as measured at qualifying implant sites. |
| NCT01531582 ↗ | Minocycline in the Treatment of Angelman Syndrome | Unknown status | University of South Florida | N/A | 2012-04-01 | There is mounting evidence to suggest that a treatment for Angelman syndrome is not just possible, but probable. The lack of known molecular targets associated with AS has hampered the development of specific therapeutics. However, a recent surge of potential therapeutics for other disorders associated with cognitive disruption has begun to be used in human clinical trials. The molecular modes of action for many of these new therapeutic agents have correlates to counter the molecular defects observed in AS. One such agent is minocycline (MC), a drug traditionally used as an antibiotic. This compound administered to a mouse model of AS showed a significant decrease in motor deficit and an increase in long term potentiation. The investigators believe a similar result will be observed when minocycline is administered to the AS patient and may lead to the development of an effective AS therapeutic. |
| NCT01539564 ↗ | Arestin - Use in Subjects With Peri-Implantitis | Completed | OraPharma | Phase 3 | 2012-04-01 | The objective of the study is to evaluate the safety and effectiveness of Arestin (minocycline HCl) 1 mg Microspheres in the treatment of subjects with peri-implantitis, when used in combination with mechanical debridement. The hypothesis of the study is that Arestin in combination with mechanical debridement is more effective in the treatment of peri-implantitis when compared to mechanical debridement alone. The primary efficacy measure will be the reduction of probing depth at Day 180 as measured at qualifying implant sites. |
| NCT01802216 ↗ | Kidney and Periodontal Disease Study | Completed | University of California, San Francisco | N/A | 2014-02-01 | The purpose of this study is (1) to determine whether a 12-month trial of patients from underserved communities with clinically significant gum disease and kidney disease randomly assigned to intensive gum disease treatment or delayed treatment is feasible and (2) to determine the variability of various tests of kidney function and inflammation in response to intensive gum disease treatment. |
| NCT02541032 ↗ | PeRiodontal Treatment to Eliminate Minority InEquality and Rural Disparities in Stroke | Unknown status | University of North Carolina, Chapel Hill | Phase 3 | 2015-12-01 | The PREMIERS study is a proposal for conducting an adequately powered two center phase III randomized controlled trial to test whether intensive periodontal treatment reduces the risk of recurrent vascular events among ischemic stroke and TIA survivors. The study uses the resources in both states including established dental centers, Joint Commission Certified Stroke Centers, the Schools of Public Health, and the Institute for Partnerships to Eliminate Health Disparities. The proposal addresses specific issues with regards to recruitment of African-American and rural stroke/TIA patients advocating the use of culturally appropriate strategies to educate the study subjects regarding stroke, periodontal disease and the periodontal stroke link. The study proposes to utilize economic evaluation of the periodontal intervention from the budgetary perspective. The focus will be on the financial sustainability of providing aggressive periodontal therapy (with certain, although relatively low expenditures) in exchange for a reduction of uncertain recurrent vascular events that may require high cost emergency department utilization and/or inpatient care. The sustainability of the proposed intervention after the completion of the project is integrally linked to the health economic assessment to show the health care cost savings. By integration with a rural primary care center, with an African American majority and households with average incomes below the state average, the study ensures that the proposed intervention to reduce stroke disparity is applicable to this target population. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ARESTIN
Condition Name
Clinical Trial Locations for ARESTIN
Trials by Country
Clinical Trial Progress for ARESTIN
Clinical Trial Phase
Clinical Trial Sponsors for ARESTIN
Sponsor Name
